Paris, France – 2 September 2021 – Orphalan SA, a Company that identifies, develops and delivers worldwide therapies for orphan diseases, today announces that the US Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the first-line treatment of Wilson’s Disease.
Accord's Generic Trientine Hydrochloride receives Approval in the US
Lupin Ltd`s Generic Trientine Hydrochloride Receives Approval In US
Lupin has received approval for its Trientine Hydrochloride Capsules USP, 250 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Syprine Capsules, 250 mg, of Bausch Health US, LLC.
Rising Pharm`s Generic Trientine Hydrochloride Receives Approval In US
Dr Reddy's Laboratories Ltd on Friday announced the launch of Trientine Hydrochloride capsules in the US market. Trientine works by removing copper from the blood. It is used to treat Wilson's disease, a genetic metabolic defect that causes excess copper to build up in the body.
Kadmon Pharma`s Generic Trientine Hydrochloride Receives Approval in US
DR REDDYS LABS LTD`s generic TRIENTINE HYDROCHLORIDE Receives Approval in US
MSN Labs` Generic Trientine Hydrochloride Receives Approval in US
Navinta's Generic Trientine Hydrochloride Receives Approval in US